Product Information
OXYBUTYNIN 2.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $1.9661 per EA under NDC 64980053101. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Dec 21, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the OXYBUTYNIN CHLORIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980053101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209025FDA Approved
12/21/2017
TE Code
AB
On Market Since
4/1/2023
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN 2.5 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9661 per EA |
|---|---|
| All-time high | $2.2176 (Apr 15, 2026) |
| All-time low | $1.9007 (Jun 19, 2024) |
| 52-week high | $2.2176 |
| 52-week low | $1.9661 |
| Median price | $2.0726 |
| Average price | $2.0570 |
| Largest weekly change | -6.6% (Sep 23, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXYBUTYNIN CHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYBUTYNIN CHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN 2.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $1.9661 per EA (NDC 64980053101), effective Sep 30, 2026.
How has the price of OXYBUTYNIN 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN 2.5 MG TABLET has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN 2.5 MG TABLET?
Since Apr 17, 2024, the NADAC for OXYBUTYNIN 2.5 MG TABLET has ranged from a low of $1.9007 (Jun 19, 2024) to a high of $2.2176 (Apr 15, 2026), with a median of $2.0726 per EA.
Are there cheaper alternatives to OXYBUTYNIN 2.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of OXYBUTYNIN 2.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OXYBUTYNIN 2.5 MG TABLET?
OXYBUTYNIN 2.5 MG TABLET (NDC 64980053101) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.